Scholarlink

Background <p>Hyperlipidemia is an established risk factor for cardiovascular disease. Limonin, a natural tetracyclic triterpenoid compound found in the traditional Chinese herb <i>Tangerine peel</i> and citrus fruits, has been shown to ameliorate hyperlipidemia, although the underlying mechanisms of action are unknown. The present study employed a comprehensive approach integrating to assess the efficacy of Limonin in the treatment of hyperlipidemia and to explore its molecular mechanisms.</p> Methods <p>Hyperlipidemia model was induced by high-fat diet (HFD). The effects of Limonin on hyperlipidemia were evaluated through serum, liver lipid, and Hematoxylin &amp; eosin (H&amp;E). Then, the mechanism of Limonin alleviates hyperlipidemia was explored by network pharmacology. Targeted metabolism was used to measure bile acids (BAs)’ changes in serum and fecal, and 16&#xa0;S rDNA sequencing of gut microbiota. Finally, the expression of genes and proteins about FXR/FGF15, ASBT, and FGF15/FGFR4 signaling pathways in the distal ileum or liver was detected by qPCR, immunohistochemistry, and Western blotting.</p> Results <p>The results confirmed the significant anti-hyperlipidemia effect of Limonin. Network pharmacology analysis revealed that Limonine alleviates hyperlipidemia is possibly closely pertaining to BAs metabolism. In a mouse model of hyperlipidemia, Limonin altered the colonic BAs profile, especially in terms of elevated levels of conjugated BAs. Limonin reshaped the structure of the gut microbiome by decreasing bile salt hydrolase (BSH)-producing genera, including <i>Lactobacillus</i>,<i> Bacteroides</i>,<i> Clostridium</i>,<i> Streptococcus</i>, and <i>Adlercreutzia</i>. Decreased BSH activity increased levels of conjugated BAs, which inhibited activation of ileum FXR, facilitated BAs synthesis and fecal BAs excretion. The decreased FXR activity resulted in lower expression of FGF15 and ASBT in the distal ileum, lower expression of FGF15 and its receptor in the liver, and increased expression of CYP7A1 in the liver.</p> Conclusion <p>Limonin remodels the gut microbiota to reduce BSH activity and to activate BAs synthesis pathways, thereby ameliorating dyslipidemia. These results provide a theoretical basis for clinical investigations into the use of Limonin in anti-hyperlipidemia therapies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Limonin attenuates hyperlipidemia by regulating the gut microbiota-bile acid-farnesoid X receptor axis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月18日

查看全文
  • Linzi Li,
  • Wen Sun,
  • Ting Tan,
  • Jinlian Xu,
  • Ying Chen,
  • Yumiao Chen,
  • Guang Gao,
  • Xu Ai,
  • Jing Zhou,
  • Yaoyao Li,
  • Daoping Zhang,
  • Shanshan Lei

摘要

Background

Hyperlipidemia is an established risk factor for cardiovascular disease. Limonin, a natural tetracyclic triterpenoid compound found in the traditional Chinese herb Tangerine peel and citrus fruits, has been shown to ameliorate hyperlipidemia, although the underlying mechanisms of action are unknown. The present study employed a comprehensive approach integrating to assess the efficacy of Limonin in the treatment of hyperlipidemia and to explore its molecular mechanisms.

Methods

Hyperlipidemia model was induced by high-fat diet (HFD). The effects of Limonin on hyperlipidemia were evaluated through serum, liver lipid, and Hematoxylin & eosin (H&E). Then, the mechanism of Limonin alleviates hyperlipidemia was explored by network pharmacology. Targeted metabolism was used to measure bile acids (BAs)’ changes in serum and fecal, and 16 S rDNA sequencing of gut microbiota. Finally, the expression of genes and proteins about FXR/FGF15, ASBT, and FGF15/FGFR4 signaling pathways in the distal ileum or liver was detected by qPCR, immunohistochemistry, and Western blotting.

Results

The results confirmed the significant anti-hyperlipidemia effect of Limonin. Network pharmacology analysis revealed that Limonine alleviates hyperlipidemia is possibly closely pertaining to BAs metabolism. In a mouse model of hyperlipidemia, Limonin altered the colonic BAs profile, especially in terms of elevated levels of conjugated BAs. Limonin reshaped the structure of the gut microbiome by decreasing bile salt hydrolase (BSH)-producing genera, including Lactobacillus, Bacteroides, Clostridium, Streptococcus, and Adlercreutzia. Decreased BSH activity increased levels of conjugated BAs, which inhibited activation of ileum FXR, facilitated BAs synthesis and fecal BAs excretion. The decreased FXR activity resulted in lower expression of FGF15 and ASBT in the distal ileum, lower expression of FGF15 and its receptor in the liver, and increased expression of CYP7A1 in the liver.

Conclusion

Limonin remodels the gut microbiota to reduce BSH activity and to activate BAs synthesis pathways, thereby ameliorating dyslipidemia. These results provide a theoretical basis for clinical investigations into the use of Limonin in anti-hyperlipidemia therapies.